What Is a KRAS Mutation and How Does It Drive Cancer?

KRAS is a gene that tells cells to build a protein that works like a growth switch, normally turned on only briefly when the body needs new cells.1Cancer Biology & Medicine. From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers A KRAS mutation leaves that switch stuck on, which makes it one of the most common drivers behind pancreatic, colorectal, and lung cancers. For decades the protein was seen as impossible to target with drugs, and that has changed only in the past few years.2PubMed Central. Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer Knowing exactly which KRAS change a tumor carries now shapes treatment choices.

How the KRAS Switch Gets Stuck On

The KRAS protein is on when it holds a molecule called GTP and off when it holds a related molecule, GDP.3Cancer Biology & Medicine. From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers Helper proteins push it into the on position when signals arrive from outside the cell, and other helpers assist it in switching itself off.4Cancer Biology & Medicine. From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers In healthy cells, growth signals pass through quickly and then stop.

To switch off, KRAS has to break GTP down, using a water molecule held in exactly the right spot.5PubMed. How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations Common mutations disturb the alignment of that water molecule, so the GTP never gets broken down.6PubMed. How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations Other mutations swap in bulkier building blocks that hold the switch-like parts of the protein in their active shape.7PubMed Central. Insight into structural dynamics involved in activation mechanism of full length KRAS wild type and P-loop mutants Either way, the protein stays on and keeps sending “grow” messages without any outside signal.

A cell with a mutated KRAS gene is not automatically cancerous, though. Healthy cells have safeguards that can stop or remove cells growing out of control, and cancers typically arise only after several changes pile up over years, often including the loss of genes that normally act as brakes on cell division.

Not every KRAS mutation behaves the same way. Different changes disturb the switch in different ways, so they differ in how strongly and how steadily the protein is held on. Some mutated versions still cycle slowly between on and off, while others are locked on much more firmly.

KRAS mutations in cancer almost always arise in the tumor itself rather than being inherited from parents. Seeing one on a tumor report doesn’t usually mean family members are at risk, and a tumor test is different from a genetic test for inherited cancer risk. If you’re unsure which kind of test your report came from, ask your care team whether it used tumor tissue or blood.

How a Stuck Switch Becomes a Growing Tumor

Active KRAS starts a chain of proteins, RAF to MEK to ERK, each switching on the next.8PubMed Central. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies The end of the chain tells the cell to keep dividing.9PubMed. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach

KRAS also switches on a second chain of proteins.10PubMed Central. KRAS mutation: from undruggable to druggable in cancer This chain helps cells grow and blocks the built-in self-destruct process that damaged cells normally go through.11PubMed Central. KRAS mutation: from undruggable to druggable in cancer KRAS also touches other pathways that control how cells move and change shape, which can help a tumor spread.12PubMed Central. KRAS mutation: from undruggable to druggable in cancer

The mutation changes how tumor cells eat, too. KRAS-driven tumors burn sugar heavily and depend on glutamine, a common nutrient.13PubMed. Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies They also gulp in proteins from around them and break them down for fuel.14PubMed. Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies15PubMed Central. Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in Cancer That lets them keep growing where nutrients are scarce.16PubMed Central. Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in Cancer

Then there are the tumor’s surroundings, including immune cells.17PubMed Central. KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies KRAS-mutant tumors release signals that calm those immune cells, and they show fewer of the flags that let immune cells spot them.18PubMed Central. KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies They can also raise PD-L1, a brake that weakens the T cells meant to kill them.19PubMed Central. Immune modulatory effects of oncogenic KRAS in cancer This hiding is a barrier to both targeted drugs and immunotherapy.20PubMed Central. KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies

Because KRAS sits near the top of several signal chains, one stuck switch feeds all of them at once, so shutting down a single downstream step often leaves the others running and the tumor keeps growing. That is why researchers are testing drug combinations that block KRAS together with a second pathway.

Which Cancers Carry KRAS Mutations and Why the Letter Code Matters

These rates vary with the population studied and the lung cancer subtype. Use them as rough guides, not personal odds.

Most mutations hit one of four hot spots in the protein, positions 12, 13, 61, and 146.28PubMed Central. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific A label like G12C means the building block glycine at position 12 became cysteine. In a code like that, the first letter is the original building block, the number is the position, and the last letter is what replaced it.

The common types cluster by cancer. G12D is most common in pancreatic and colorectal cancers, G12V in uterine, and G12C in lung cancer.29PubMed Central. Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China G12C, G12D, and G12V are different mutations and not interchangeable, since a drug built for one specific variant generally does not work on the others. Treatment eligibility often depends on the exact code, so it is worth asking whether your report lists the specific variant rather than only “KRAS positive.”

Drugs That Now Target KRAS

KRAS grips its fuel molecule extremely tightly, so drugs couldn’t outcompete it.30PubMed Central. Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer Its surface also has few deep pockets for a drug to fit into.31PubMed Central. Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer Early attempts failed.

Sotorasib and adagrasib target only the G12C mutation.32PubMed Central. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade They fit a pocket that is open when KRAS is off and lock onto the mutant cysteine, keeping the protein permanently off.33PubMed Central. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade Side effects of these drugs commonly involve digestive and liver changes, so regular scans and blood tests check both how well the drug is working and whether it is safe.

Drugs aimed at G12D, such as MRTX1133 and zoldonrasib, are in development.34PubMed. Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies35PubMed. Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V Pan-RAS and pan-KRAS drugs like daraxonrasib aim to cover many mutation types at once.36PubMed. Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies37PubMed. Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V Newer “ON” blockers attack KRAS while it’s switched on.38PubMed. Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies39PubMed Central. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

Trials are usually open only to a specific variant. Ask whether a clinical trial for your KRAS type is currently enrolling, and whether it suits your stage and prior treatments. ClinicalTrials.gov lets you search by condition and mutation, though your care team can help judge which listings fit you. Approval status differs by country and cancer type, so a drug approved for lung cancer may not be an established option for another cancer.

Why KRAS Drugs Can Stop Working

Despite early benefit, resistance to G12C drugs often emerges quickly.40PubMed. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity One cause is that new KRAS mutations can change the drug pocket so the drug can’t bind.41PubMed Central. A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors Tumors can also bypass KRAS through changes in other genes like EGFR, BRAF, or MET.42PubMed Central. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer Even so, in one group of 38 patients, a clear cause was found in fewer than half.43PubMed Central. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer

Resistance varies because drug treatment favors whichever tumor cells happen to survive, and they may use different escape routes in different people. That is also why testing again at progression can be useful.

Progression usually shows up on a scan as growth after a period of shrinking or stability, sometimes before any new symptoms. Doctors may repeat tumor or blood testing to look for the new cause of resistance, and the result can point toward a different drug or a clinical trial. Resistance does not mean the first drug was the wrong choice; most targeted drugs eventually meet resistance, and the period of control still counts.

Researchers are pairing KRAS drugs with other treatments. Combining KRAS drugs with other targeted drugs showed activity in lab-grown patient tumor cells.44Cancer Research Communications. Data from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types Adagrasib plus immunotherapy improved survival in mice with brain tumors.45PubMed Central. Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis Getting that combination to work in people has proven hard so far.46PubMed. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity

How KRAS Testing Is Done

Tumor tissue from a biopsy is the standard sample. A liquid biopsy instead looks for tumor DNA floating in a blood sample.47PubMed Central. Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review In colorectal cancer, one blood test returned results in 7 days versus 22 for tissue, matching tissue about 83% of the time.48PubMed Central. Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review In lung cancer, though, blood tests missed about a third of tumors that had KRAS mutations, while false alarms were rare.49PubMed Central. KRAS Mutations in Circulating Tumor DNA for Lung Cancer Diagnosis: A Comprehensive Meta-Analysis A negative blood result may therefore need tissue testing to confirm.

Blood testing is useful when a biopsy would be risky or when there is too little tissue to test. Some doctors order both at diagnosis to speed up results while keeping the tissue backup. Ask how long each result takes, since treatment decisions may wait on it.

These tests guide treatment after cancer has been found. They are not screening tests for healthy people.

What a KRAS Result Means for Your Outlook

In metastatic colorectal cancer, RAS testing decides eligibility for anti-EGFR antibody drugs.50PubMed Central. Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review Those drugs are generally not used when KRAS is mutated. They work by blocking a receptor upstream of KRAS, so a stuck KRAS switch can keep signaling no matter what happens at the receptor. KRAS-mutant tumors’ immune hiding can also blunt the response to immunotherapy.51PubMed Central. KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies

How much a KRAS mutation affects outlook depends on the cancer type and the specific variant, so there is no single answer. Stage, overall health, and other genetic changes in the tumor also shape what to expect. Treatment for KRAS-mutant cancers is changing quickly, so older statistics may not reflect what is available now.

Useful questions for your care team:

  • Which exact KRAS variant does my tumor have?
  • Does it make me eligible for, or exclude me from, any treatments?
  • Are there trials for my variant?
  • Were other genes tested alongside KRAS?
  • Should I be retested if the cancer grows?